anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: This study aims to determine the association between pre- and postoperative radiotherapy (PORT) circulating tumor DNA (ctDNA) dynamics and oncological outcomes in patients with residual triple-negative breast cancer who underwent surgery after neoadjuvant chemotherapy (NAC).
MATERIALS AND METHODS: Between March 2019 and July 2020, 11 nonmetastatic patients with residual disease who underwent surgery after NAC were prospectively enrolled. In each patient, tumor specimens obtained during surgery and blood samples collected at three time points during PORT (T0: pre-PORT, T1: 3 weeks after PORT, T2: 1 month after PORT) were sequenced, targeting 38 cancer-related genes. Disease-free survival (DFS) was evaluated and the association between DFS and ctDNA dynamics was analyzed.
RESULTS: At T0, ctDNA was detected in three (27.2%) patients. The ctDNA dynamics were as follows: two showed a decreasing ctDNA variant allele frequency (VAF) and reached zero VAF at T2, while one patient exhibited an increasing VAF during PORT and maintained an elevated VAF at T2. After a median follow-up of 48 months, two patients experienced distant metastasis without any locoregional failures. All failures occurred in patients with ctDNA positivity at T0 and a decreased VAF after PORT. The 4-year DFS rates according to the T0 ctDNA status were 67% (positive ctDNA) and 100% (negative ctDNA) (p=0.032).
CONCLUSION: More than a quarter of the patients with residual disease after post-NAC surgery exhibited pre-PORT ctDNA positivity, and ctDNA positivity was associated with poor DFS. For patients with pre-PORT ctDNA positivity, the administration of a more effective systemic treatment should be considered.
A cosmetic composition containing Rubus coreanus extract is provided to suppress formation of SNARE complex and to improve anti-wrinkling. A cosmetic composition for improving anti-wrinkling contains 0.0001-30 weight% of Rubus coreanus extract as an active ingredient. The Rubus coreanus extract is obtained from fruit of Rubus coreanus Miquel using 80% ethanol. The Rubus coreanus is pretreated by steaming at 120-150[deg.]C for 3-6 hours, roasting at 100-180[deg.]C for 10 minutes to one hour and 80-100[deg.]C for 10 minutes to one hour.
Acute kidney injury (AKI) results from the rapid deterioration of renal function, which is mainly treated by transplantation and dialysis, and has a high mortality rate. Inflammation induced by excess reactive oxygen/nitrogen species (RONS) plays a crucial role in AKI. Although small molecule antioxidants have been utilized to alleviate AKI, low bioavailability and side-effect of these drugs tremendously limit their clinical use. Hence, we successfully construct ultra-small (2-4 nm) rhodium nanoparticles modified with l-serine (denoted as Rh-Ser). Our results show that Rh-Ser with multiple enzyme-mimicking activities, allows remove various RONS to protect damaged kidney cells. Additionally, the ultrasmall size of Rh-Ser is conducive to enrichment in the renal tubules, and the modification of l-serine enables Rh-Ser to bind to kidney injury molecule-1, which is highly expressed on the surface of damaged renal cells, thereby targeting the damaged kidney and increasing the retention time. Moreover, Rh-Ser allows the production of oxygen at the inflammatory site, thus further improving hypoxia and inhibiting pro-inflammatory macrophages to relieve inflammation, and increasing the survival rate of AKI mice from 0 to 80%, which exhibits a better therapeutic effect than that of small molecule drug. Photoacoustic and fluorescence imaging can effectively monitor and evaluate the enrichment and therapeutic effect of Rh-Ser. Our study provides a promising strategy for the targeted treatment of AKI via RONS scavenging and inflammatory regulation.
PURPOSE:To provide an enteric soft capsule soluble completely in the intestines and producible in a safe working environment, by coating the surface of a gelatin soft capsule with a water-soluble crosslinkable polysaccharide which can be crosslinked with a specific cation. CONSTITUTION:An enteric soft capsule can be produced by coating the surface of a gelatin soft capsule with a water-soluble crosslikable polysaccharide which can be crosslinked with >=2-valent cations, preferably calcium ion. the gelatin soft capsule may be undried gelatin soft capsule or dried gelatin soft capsule. The crosslinkable polysaccharide is preferably sodium alginate, low-methoxyl pectin, etc. The coating film can be formed by immersing a gelatin soft capsule in an aqueous solution of the above polysaccharide and then immersing in an aqueous solution containing the above cation. A soft capsule having excellent enteric function can be produced without using an organic solvent.
PCPs will conduct primary care as usual, without the support of the NCM. At the baseline visit, patient participants receive an educational pamphlet and view a short video on overdose and cancer screening. The pamphlet includes information about preventing opioid-related overdose, including how to obtain a naloxone kit. The video content will feature the health benefits of exercise. It will be viewed on a tablet or desktop computer and will be approximately 2 minutes long. All EUC patient participants receive the same video, which is not tailored to the responses given on their questionnaires. There is no study intervention after the baseline visit.
BACKGROUND: Patients admitted to the neuroscience intensive care unit often experience varying states of confusion and restlessness. The purpose of this study was to examine restlessness in acutely confused patients through use of familiar photographs. METHODS : This randomized prospective pilot study placed family photographs (photos) on the bedrail of confused patients during the night shift (8 pm to 4 am ) in a neuroscience intensive care unit. Wrist actigraphy was used to examine restlessness when patients were turned to face the photos versus when they were not facing the photos. RESULTS: The 20 patients enrolled provided 34 nights worth of data during which 32 640 actigraph readings were obtained. On the first night of study, the odds of wrist movement were higher when the patient was facing the photos compared with not (odds ratio, 1.51; 95% confidence interval, 1.42-1.61). During subsequent nights, the odds of wrist movement were lower when the patient was facing the photos compared with not (odds ratio, 0.82; 95% confidence interval, 0.75-0.90). CONCLUSION : Use of familiar photos does not change restlessness, agitation, or delirium on the first night of observation. However, the use of familiar photos may decrease restlessness on the subsequent nights. There are important subjective observations from researchers and family that suggest all subjects had a noticeable response when initially seeing the familiar photos.
The ENHANCE program was tailored to address the current health and well-being challenges faced by individuals living in the COVID-19 pandemic. The contents of each week will focus on a new evidenced-based principle that has been shown in research to decrease negative thinking and emotions, as well as increase positive thinking, emotions, and overall physical and mental health and well-being. Each week participants will focus on the skills and methods of implementing happiness and well-being into their daily routine.
PROBLEM TO BE SOLVED: To obtain the subject external agent capable of improving rough skin attributable to atopic dermatitis, sensitive skin and skin xerosis and useful as a treating agent for eczema such as atopic dermatitis by compounding a specific compound in combination with a betaine. SOLUTION: This agent is composed of (A) one or more kinds of compounds selected from dipotassium glycyrrhizinate, glycyrrhizic acid and stearyl glycyrrhizinate and (B) a betaine (e.g. trimethyl glycine) as active components. Further, e.g. 0.1-2wt.% component A and 1-5wt.% component B are preferably compounded in the preparation. Regarding dosage, it is preferable that the agent is applied 1-5 times a day and a single coating dose is 0.25-15mg of the component A and 2.5-50mg of the component B.
Olanzapine may induce orthostatic hypotension associated with dizziness, tachycardia, bradycardia and, in some patients, syncope, especially during the initial dose-titration period, probably reflecting its α1-adrenergic antagonistic properties [see Patient Counseling Information (17)].

From an analysis of the vital sign data in an integrated database of 41 completed clinical studies in adult patients treated with oral olanzapine, orthostatic hypotension was recorded in ≥20% (1277/6030) of patients. 

For oral olanzapine therapy, the risk of orthostatic hypotension and syncope may be minimized by initiating therapy with 5 mg QD [see Dosage and Administration (2)]. A more gradual titration to the target dose should be considered if hypotension occurs. 

Hypotension, bradycardia with or without hypotension, tachycardia, and syncope were also reported during the clinical trials with intramuscular olanzapine for injection. In an open-label clinical pharmacology study in nonagitated patients with schizophrenia in which the safety and tolerability of intramuscular olanzapine were evaluated under a maximal dosing regimen (three 10 mg doses administered 4 hours apart), approximately one-third of these patients experienced a significant orthostatic decrease in systolic blood pressure (i.e., decrease ≥30 mmHg) [see Dosage and Administration (2.4 )]. Syncope was reported in 0.6% (15/2500) of olanzapine-treated patients in phase 2 to 3 oral olanzapine studies and in 0.3% (2/722) of olanzapine-treated patients with agitation in the intramuscular olanzapine for injection studies. Three normal volunteers in phase 1 studies with intramuscular olanzapine experienced hypotension, bradycardia, and sinus pauses of up to 6 seconds that spontaneously resolved (in 2 cases the reactions occurred on intramuscular olanzapine, and in 1 case, on oral olanzapine). The risk for this sequence of hypotension, bradycardia, and sinus pause may be greater in nonpsychiatric patients compared to psychiatric patients who are possibly more adapted to certain effects of psychotropic drugs. For intramuscular olanzapine for injection therapy, patients should remain recumbent if drowsy or dizzy after injection until examination has indicated that they are not experiencing postural hypotension, bradycardia, and/or hypoventilation.

Olanzapine should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, and conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications) where the occurrence of syncope, or hypotension and/or bradycardia might put the patient at increased medical risk.

Caution is necessary in patients who receive treatment with other drugs having effects that can induce hypotension, bradycardia, respiratory or central nervous system depression [see Drug Interactions (7)]. Concomitant administration of intramuscular olanzapine and parenteral benzodiazepine is not recommended due to the potential for excessive sedation and cardiorespiratory depression.
Over the last 15 years, robot-assisted laparoscopic radical prostatectomy surgery has seen a considerable rise in France. To date, it represents the most common surgical technique for radical prostatectomies, compared with standard procedure such as open retropubic radical prostatectomy or laparoscopic radical prostatectomy (8000 procedures/year, 40% of surgeries). In 2016, the French Health Authority (HAS) published a report on the robot-assisted laparoscopic radical prostatectomy practice that highlighted the small amount of available convincing data to provide evidence for a significant clinical benefit. There were no published data on overall or progression-free survival compared with other surgical procedures, with an important organizational and financial impact for healthcare institutions and patients. The question of the clinical benefit and the cost-effectiveness ratio of this surgical procedure is still relevant taking into account that randomized studies are difficult to carry out and that results of prospective registers will be available in many years. In this context, the use of the French National Claims Database (SNDS) appears to be the best short-term and reduced-cost solution to identify patients who benefited from the three surgical procedures since the rise of robotics. It would provide real-life data to national institutions in order to conclude on the opportunity to set a specific hospital tariff for the robot-assisted laparoscopic radical prostatectomy. This study aims to assess the cost-effectiveness ratio and the clinical benefit (survival, disease recurrence, functional results) of the robot-assisted laparoscopic radical prostatectomy compared with other procedures using real-life data from SNDS. The population of patients who benefited from robot-assisted surgery will be identified in the SNDS through a practices survey, allowing the identification of centres fully converted to robotics.
PURPOSE: To obtain a medicine inhibiting attaching or invasion, etc., of a leukocyte onto intravascular endothelial cells of a digestive tract induced by a stress, etc., and useful for prevention or curing of acute gastritis or gastric ulcer, etc., by using a P-selectin inhibitor as an active component. CONSTITUTION: This medicine contains a P-selectin inhibitor as an active component. As the inhibitor, e.g. an anti P-selectin antibody or a ligand of a P-selectin is exemplified. As the ligand, concretely, e.g. glycoprotein or glycolipid on the surface of a leukocyte, etc., is exemplified. The objective medicine is preferably administrated into vein by dissolving or suspending in an aqueous carrier such as water or physiologic saline. The administrating amount is preferably 5-3,000mg/day to a patient having 70kg body weight.
In controlled clinical trials, the total incidence of adverse reactions associated with the use of desonide cream, 0.05% was approximately 1%. These adverse reactions were pruritus, pain, folliculitis, rash, peripheral edema, pustular rash, sweating, erythema, irritation, and burning. Laboratory abnormalities were found in 3% of the patients. These were hyperglycemia (2%) and liver function abnormality (1%).

The following additional local adverse reactions have been reported infrequently with topical corticosteroids, and they may occur more frequently with the use of occlusive dressings and higher potency corticosteroids. These reactions are listed in approximate decreasing order of occurrence: dryness, folliculitis, acneiform eruptions, perioral dermatitis, allergic contact dermatitis, secondary infection, skin atrophy, striae, miliaria, burning and hypopigmentation.
PURPOSE: To obtain a hair cosmetic imparting hair an excellent gloss and wet feeling and a smooth touch without oil staining of hair, having excellent elonga tion and fitting to hair, and having suitable setting force by comprising an amphoteric polymer, a complex material and water. CONSTITUTION: In this hair cosmetic, 0.05-15wt.% of a polymer of the formula is used as an amphoteric polymer (R1 is H or methyl; R2 and R5 are each a 1-4C unsaturated hydrocarbon; R3 and R4 are each H or a 1-4C saturated hydrocarbon; A is O, NH or none). The complex material is composed of 0.05-30wt.% of an amphoteric surfactant and/or a semipolar surfactant and 0.05-20wt.% of a higher fatty acid (e.g. lauric acid). Further, the cosmetic contains water and suitable amount of an oily component, a water-soluble polymer, a humectant, an antioxidant, an ultraviolet absorber, a surfactant, an antiseptic agent, a drug and a fragrance, etc. The cosmetic is an excellent hair cosmetic having extremely improved dispersion stability without mixing an oily component such as a silicone oil.
The use of partially-automated systems require drivers to supervise the system functioning and resume manual control whenever necessary. Yet literature on vehicle automation show that drivers may spend more time looking away from the road when the partially-automated system is operational. In this study we answer the question of whether this pattern is a manifestation of inattentional blindness or, more dangerously, it is also accompanied by a greater attentional processing of the driving scene. Participants drove a simulated vehicle in manual or partially-automated mode. Fixations were recorded by means of a head-mounted eye-tracker. A surprise two-alternative forced-choice recognition task was administered at the end of the data collection whereby participants were quizzed on the presence of roadside billboards that they encountered during the two drives. Data showed that participants were more likely to fixate and recognize billboards when the automated system was operational. Furthermore, whereas fixations toward billboards decreased toward the end of the automated drive, the performance in the recognition task did not suffer. Based on these findings, we hypothesize that the use of the partially-automated driving system may result in an increase in attention allocation toward peripheral objects in the road scene which is detrimental to the drivers' ability to supervise the automated system and resume manual control of the vehicle.
Darbepoetin alfa is an erythropoiesis-stimulating protein that is produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology. Darbepoetin alfa is a 165-amino acid protein that differs from recombinant human erythropoietin in containing 5 N-linked oligosaccharide chains, whereas recombinant human erythropoietin contains 3 chains. The 2 additional N-glycosylation sites result from amino acid substitutions in the erythropoietin peptide backbone. The approximate molecular weight of darbepoetin alfa is 37,000 daltons.

Aranesp (darbepoetin alfa) injection is formulated as a sterile, colorless, preservative-free solution containing polysorbate for intravenous or subcutaneous administration. Each 1 mL contains polysorbate 80 (0.05 mg), sodium chloride (8.18 mg), sodium phosphate dibasic anhydrous (0.66 mg), and sodium phosphate monobasic monohydrate (2.12 mg) in Water for Injection, USP (pH 6.2 ± 0.2).
Patients at local physician clinics as well as my own clinic will be enrolled at the time they are evaluated for having COVID-19. Patients enrollment will be voluntary and based upon their request for treatment with Ivermectin. These patients will be questioned on symptoms and the timing of those symptoms in detail. They will then be followed throughout their treatment course to evaluate their recovery experience. Detailed accounts of their symptoms and their resolution will be followed. The study patients will stop being followed when they are either admitted to the hospital or are deemed to be symptom free. Any other medications prescribed to the patients will also be tracked. Medical histories will be taken and documented to make comparisons at the end of the study. Those patients not requesting Ivermectin will also be followed for comparisons at a later date.
Children (3-5 years) who were diagnosed and treated because of positional plagiocephaly are included in this group. An asssessment of posture will be performed.
BACKGROUND: As a traditional digestive medicine, stir-fried Raphani Semen (SRS) has been used to treat food retention for thousands of years in China. Modern research has shown that SRS has a good therapeutic effect on functional dyspepsia (FD). However, the active components and mechanism of SRS in the treatment of FD are still unclear.
OBJECTIVE: The purpose of this study is to elucidate the material basis and mechanism of SRS for treating FD based on UPLC-Q-Exactive Orbitrap MS/MS combined with network pharmacology and molecular docking.
METHODS: The compounds of SRS water decoction were identified by UPLC-Q-Exactive Orbitrap MS/MS and the potential targets of these compounds were predicted by Swiss Target Prediction. FD-associated targets were collected from disease databases. The overlapped targets of SRS and FD were imported into STRING to construct Protein-Protein Interaction (PPI) network. Then, the Metascape was used to analyze Gene Ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway after introducing overlapped targets. Finally, the active components and core targets were obtained by analyzing the "component-target-pathway" network, and the affinity between them was verified by molecular docking.
RESULTS: 53 components were identified, and 405 targets and 1487 FD-related targets were collected. GO and KEGG analysis of 174 overlapped targets showed that SRS had important effects on hormone levels, serotonin synapses, calcium signaling pathway and cAMP signaling pathway. 7 active components and 15 core targets were screened after analyzing the composite network. Molecular docking results showed that multiple active components had high affinity with most core targets.
CONCLUSION: SRS can treat FD through a variety of pathways, which provides a direction for the modern application of SRS in FD treatment.
The 24 study participants will be administered the Nicorette lozenge containing 4 mg of nicotine on one occasion. Blood samples will be obtained for 4 hours for analysis of nicotine plasma levels.
The invention belongs to the technical field of biological pharmacy, and concretely relates to a ganoderma lucidum mycelium and a preparation method thereof. The formula comprises poria, Chinese caterpillar fungus, lasiosphaera seu calvatia, herba artemisiae annuae, radix rehmanniae preparata, radix polygalae, rhizoma atractylodis macrocephalae, radix pseudostellariae, radix glycyrrhizae, radix astragali, prepared common monkshood daughter root, ramulus cinnamomi, herba epimedii, radix morindae officinalis, manyflower solomonseal rhizome, radix ophiopogonis, rhizoma polygonati odorati, fructus schisandrae chinensis, fructus trichosanthis, pericarpium citri reticulatae, radix arnebiae, periostracum cica, jujube, rhizoma dioscoreae, fructus rosae laevigatae, black rice, honey, medicated leaven, fructus hordei germinatus and red rice. The ganoderma lucidum mycelium is abundant in multiple nutrition and has relatively high medicinal value. Concretely, the ganoderma lucidum mycelium helps to heal wound, and ganoderma lucidum water is capable of phagocytosing bacteria, inhibiting growth of bacteria and helping wound to diminish inflammation and relieving pain. The product has relatively good beauty-maintaining efficacy, and enables skin to be elastic and appearance to be relatively young after being eat for a long time. Additionally, the production cost is not high, the preparation is simple, and the preparation method is suitable for popularization and usage in correlated technology field.
The invention discloses a traditional Chinese medicine preparation for treating transient synovitis of hip in children. Transient synovitis of hip in children is a non-specific inflammation in hip and belongs to traditional Chinese medicine arthralgia syndrome. According to the invention, traditional Chinese medicines including yerbadetajo herb, phoenix hawksbeard root, Crneate Lespedeza, Habenaria stenostachya(lindl.)Benth., geum japonicum, amphicome, Cynanchum wallichii Wight, Cyclosorus dentatus(Forsk.) Ching and vacciniumfragile are detected with water to obtain a decoction. Through clinical tests, total effective rate reaches 96.97%. There is no obvious adverse reaction during therapeutic process of children. It shows that the traditional Chinese medicine preparation has a remarkable curative effect of treating transient synovitis of hip in children. The traditional Chinese medicine preparation is safe and reliable and is worthy of clinical promotion.